IGLL5 and Hodgkins lymphoma: CD79 has been extensively studied in hematological tumors and has been reported to be more positive in elderly Hodgkin’s lymphoma patients with poor prognosis (Sakatani et al., 2020); however, IGLL5 and LHFPL2 are less often studied in tumors and their functions remain unknown.